The independent source for health policy research, polling, and news.
461 - 480 of 688 Results
Federal officials are allowing the private insurance plans to use âstep therapyâ for drugs administered by doctors. In step therapy, patients must first use cheaper drugs to see if they work before receiving more expensive options.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
As HHS decided to cut $1.6 billion in drug payments to hospitals, it weighed thousands of comments generated by a pharmaceutical-funded advocacy group.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
Alec Raeshawn Smith was 23 when diagnosed with Type 1 diabetes, and 26 when he died. He couldn't afford $1,300 per month for his insulin and other diabetes supplies. So he tried to stretch the doses.
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharmaâs pricing.
California legislators approved some significant health care proposals in their rush to meet the Friday end-of-session deadline. They tackled controversial topics, such as making abortion pills available on college campuses, and adopted measures countering Trump administration attacks on the Affordable Care Act.
In this episode of KHNâs âWhat the Health?â Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico answer listenersâ questions about health policy and politics.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
In this episode of KHNâs âWhat the Health?â Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner talk about the latest Trump administration efforts to address high drug prices, whatâs next for short-term health insurance plans and insider trading charges against a New York GOP congressman.
Inspector general identifies possible problems in nearly 23 percent of pharmacies that bill Medicare for blended creams, gels and lotions.
The number of diabetes drug prescriptions filled for low-income people enrolled in Medicaid rose sharply in states that expanded eligibility for the program under the Affordable Care Act, according to a new study.
KHNâs newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you donât have to.
The Trump administration signals it is willing to consider such a move if it is carefully tailored to focus solely on specific situations where a high-priced drug is made by one company.
KHNâs newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you donât have to.
In this episode of KHNâs âWhat the Health?â Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Alice Ollstein of Talking Points Memo and Kimberly Leonard of the Washington Examiner talk about the new push on health legislation by Republicans in the House, as well as developments on Medicaid work requirements, drug prices and the fate of children separated from their parents at the U.S.-Mexican border. Plus, for extra credit, the panelists offer their favorite health stories of the week.
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
KHNâs newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you donât have to.
In this episode of KHNâs âWhat the Health?â Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico, and Erin Mershon of Stat News discuss a series of health policy court decisions on everything from prescription drug discounts to soda taxes. Plus, Rovner, interviews health care futurist and consultant Jeff Goldsmith.
Š 2026 KFF